Your session is about to expire
← Back to Search
VTX002 for Ulcerative Colitis
Study Summary
This trial is testing a new drug to see if it's safe and effective in treating moderate to severe ulcerative colitis. Up to 180 participants will be given the new drug daily for 28 days to 13 weeks, and then followed for up to 36 months.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: VTX002 Dose A
- Group 2: VTX002 Dose B
- Group 3: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has VTX002 been granted regulatory approval by the FDA?
"Our team at Power judged VTX002's safety to be a 2, as we have evidence of its security but no proof yet that it is effective."
What criteria must be met in order to partake in this medical experiment?
"Eligibility criteria for this trial is restricted to individuals aged between 18 and 80 who suffer from ulcerative colitis; the recruitment process requires 180 subjects."
Does this research accept participants aged 55 or older?
"This clinical trial requires participation from individuals aged 18 to 80. There are 65 trials for minors and 341 studies available for elderly patients."
Are recruitment efforts still ongoing for this experiment?
"The information hosted on the clinicaltrials.gov website confirms that this study is currently recruiting for participants, and was posted initially on November 30th 2021, with its most recent update being 11/4/2022."
What is the recruitment rate for this experiment?
"To properly conduct the trial, Oppilan Pharma Ltd will need to enlist 180 participants that meet their predetermined criteria. The sponsor is managing operations at two medical centres in Myrtle Beach and Winston-Salem, South carolina (Local Sites #840045 & 840047)."
How many healthcare locations are participating in this investigation?
"This trial is running at 30 distinct medical centres, the most notable of which encompass Myrtle Beach, South carolina (840045), Winston-Salem, North carolina (840047) and Shreveport, Louisiana (840042)."
Share this study with friends
Copy Link
Messenger